OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development
2025.Apr.23
Corporate
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs),
GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.
2025.Mar.28
Corporate
GlycOBI® Advances Bispecific and Dual Payload ADC Development
OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston
2025.Mar.26
Corporate
Award & Certification
OBI Wins " Most Promising Immunotherapy Pipeline" Award
Showcasing TROP2 ADC Research at Biologics World Taiwan
2025.Mar.18
Corporate
New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over
2025.Mar.12
Corporate
Award & Certification
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
2025.Mar.03
Corporate
OBI Pharma Invited to Host Workshop at World ADC London
Sharing ADC Development Insights and Unveiling Linker Technology Details for the First Time
2025.Mar.02
Corporate
OBI Pharma's GlycOBI® Platform Gains Attention at Nanjing Summit
Optimized Process Design and CMC: Key to Next-Generation ADC Development
2025.Feb.20
Corporate
OBI Pharma Showcases Proprietary ADC Platform GlycOBI® in China
Drawing Strong Industry Interest
2025.Feb.19
Corporate
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics